Cor Vasa 2023, 65(4):643-646 | DOI: 10.33678/cor.2022.113

(Gliflozins, chronic heart failure, and chronic kidney disease - a review and our initial experience)

Jakub Flašík, Miloš Táborský

I. interní klinika - kardiologická, Lékařská fakulta Univerzity Palackého v Olomouci a Fakultní nemocnice Olomouc, Olomouc

While, as a class of drugs, gliflozins were originally developed as oral antidiabetic agents, these molecules have been shown in recent years to exert clinically significant effects also in indications such as chronic heart failure and chronic kidney disease. These beneficial actions of both empagliflozin and dapagliflozin have been documented in several studies irrespective of the presence or absence of type-2 diabetes. It were particularly their nephroprotective effects which were consistently observed regardless of the individual studies' primary goals. At present, the two gliflozins play an important role in the management of chronic heart failure with reduced ejection fraction and have been included in the latest guidelines accordingly.

Keywords: Chronic kidney disease, Gliflozins, Heart failure

Received: October 7, 2022; Revised: October 7, 2022; Accepted: October 20, 2022; Published: September 1, 2023  Show citation